aflibercept Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Unknown (1)

Observational (1)

National Cancer Institute, Naples (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadcancer

I am/have/hadvascular endothelial growth factor

I am/have/hadvegf

I am/have/hadfolfiri regimen

I am/have/hadcolorectal cancer

I am/have/hadmetastatic colorectal cancer

I am/have/hadEGFR

added new label for I am/have/had

more

I am looking for

I am looking foraflibercept

I am looking forvascular endothelial growth factor

I am looking forvegf

I am looking forbevacizumab

I am looking foroxaliplatin

I am looking forgrowth factor

I am looking forfluoropyrimidine

I am looking forangiogenesis inhibitors

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For Seniors
For adults
Recruiting in 100s
Observational Study
all
Recruiting

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

In this group of patients the use of anti-angiogenic drugs (bevacizumab and aflibercept) is predominant. Still to date there are no studies to guide oncologists in the selection of the best anti-angiogenic drug (bevacizumab beyond progression vs aflibercept) after failure of the first-line chemotherapy in RAS-M mCRC patients.

vegf

folfiri regimen

cancer

colorectal cancer

metastatic colorectal cancer

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.